Farmas USA

Empresa realmente muy interesante, estaba viendo su presentación de marzo de este año:

https://www.advaxis.com/wp-content/uploads/2018/03/March-2018-Corporate-Presentation-Final.pdf

Pues algo se nos escapa para que solo baje y baje y baje y,...

ADXS

TSLA

Noticia de hoy en el periódico...

Tesla llama a revisar 123.000 coches por problemas en la dirección asistida

http://www.elmundo.es/motor/2018/03/30/5abe043ae2704e3d3f8b45cf.html

PGNX 

No parece mala idea entrar a buscar profit de cara a los proximos catalizadores pues sin dudas se volvera a calentar otra vez , por lo menos seguro a cerrar ese gap y por ahora se apoya en la EMA 33 que le esta haciendo de soporte donde podria hacer lateralidad/Acumulacion hasta que ese MACD se vuelva a girar y mientras el Mass Index y el Chaiking Money Flow , dicen que esta entrando capital 

----............................    -----------------------  

Progenics Pharmaceuticals: Don't Worry About Azedra's PDUFA Delay

Summary

On March 22, Progenics announced that the FDA had delayed its PDUFA decision for drug candidate Azedra by 3 months; the new PDUFA action date is July 30.

The delay is apparently due to the submission of supplemental Chemistry, Manufacturing, and Controls information that the FDA requires further time to review.

Shares fell sharply on news of the delay; some investors preparing for an April catalyst and now faced with a longer wait decided to bail.

Azedra treats malignant adrenal gland tumors for which there is currently no FDA-approved treatment.

Despite the delay, this ultra-orphan therapy remains on track to win approval, and should yield very significant financial rewards for the company and its shareholders.

https://seekingalpha.com/article/4159894-progenics-pharmaceuticals-worry-azedras-pdufa-delay?ifp=0&app=1

AKAO 

No esta mal subirse al tren ./ ...PDUFA date is June 25, 2018. 

---

Achaogen: Not Too Late To Catch The Rally   Mar. 23, 2018 12:21 PM ET

 About:  Achaogen (AKAO)

Bret Jensen

Summary

Small biopharma Achaogen has bucked the downward trend of the market this week.

Upcoming FDA approval could see the rally continue. One insider continues to add to his big stake in this name.

Achaogen was awarded a contract valued at up to $18.0 million in grant funding from BARDA to support the development of C-Scape, which has been awarded Qualified Infectious Disease Product status by the FDA.

https://seekingalpha.com/article/4158492-achaogen-late-catch-rally

SGYP 

Short Interest decreciente

Patron Mornig Star o parecido , tras la ultima vela - Doble suelo en zona donde Stockastico en sobre venta comienza Golden Croos y RSI 40 .MACD empieza a dar tenues signos de giro

Además la paralización de la FDA de ese ensayo conjunto con AstraZeneca no ayuda la verdad.....

En la conferencia sobre la publicación de los últimos resultados, comentaron que hasta el segundo cuatrimestre de 2019 tendrían fondos suficientes para seguir con su actividad, así que esperamos que no haya más ampliaciones este año.

TONY LOMBARDO- EMA: "we were delighted to announce the submission of a conditional marketing authorization application through the European Medicine Agencies for our lead LM technology product candidate, AXAL, for the treatment of adult women who progressed beyond first line therapy for persistent, recurrent or metastatic cervical cancer. This is a significant milestone for Advaxis as it represents our first marketing application for a product approval of our LM technology. The MAA package, we have prepared for EMA evaluation includes the totality of the data, including Phase 2 results from GOG-0265 as well as supportive data from other clinical trials evaluating AXAL. This will be a 13-month review process."   

TONY: "We also continued to enroll patients in our Phase 3 global AIM2CERV study of AXAL to treat higher risk locally advanced cervical cancer. We are enrolling patients in 13 countries and look forward to providing an update on this program midyear as planned."

TONY; " agreement with Bristol-Myers Squibb, which will evaluate their PD-1 inhibitor, Opdivo in combination with AXAL in the advanced trial. This is a global randomized registrational quality trial to evaluate this combination in women with recurrent metastatic cervical cancer who have failed at least one prior line of systemic chemotherapy. We expect to initiate the study by calendar year 2018"

TONY: "Phase 1/2 study evaluating ADXS-PSA as a monotherapy and in combination with Merck’s checkpoint inhibitor, Keytruda. There are currently few therapeutic options available to patients with the stage of prostate cancer."

TONY: "ADXS-HOT, we have designed more than 10 off-the-shelf products, which we believe maybe capable of generating potent tumor-specific and high-strength killer T-cells.H OT products will be available for patients to start treatment immediately.The HOT technology has strong IP position with protection into 2038 and an IP filing strategy that provides for broad coverage opportunities across multiple diseases in combination therapies. We expect to initiate first-in-human studies in non-small cell lung cancer by the end of 2018."

Las otrsa dos veces, que hizo la escalada hasta los 30$, el RSI avisó, así que espero una tercera vez.

ADXS

graficos semanales

XBI ... podia haberlo hecho mejor pero me conformo por ahora con esa sobra inferior marcando distancia de la alcista. Dado el doji en diario ... no descartaria un retest de dicha alcista ...ya veremos ...

SPY

Harami cross bullish ... teoricamente patron de aviso de cambio de tendencia , veremos si confirma ...